Clinical trial NCT00333502: Study of CRLX101 (NLG207) in the Treatment of Advanced Solid Tumors
Official title: A Phase 1b/2a Safety and Pharmacokinetic Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Cancer
Solid Tumor
Keywords: Cancer, Neoplasms, Solid Tumor, Ovarian Cancer, Lung Cancer,
Non Small Cell Lung Cancer, Pancreatic Cancer,
Breast Cancer, Colon Cancer, Endometrial Cancer,
Kidney (Renal Cell) Cancer, Melanoma, Prostate Cancer,
Skin Cancer, Thyroid Cancer,
Solid Malignancies
Lead sponsor: Lumos Pharma
Sponsor class: INDUSTRY
First posted: 2006-06-05
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: CRLX101 is a nanopharmaceutical comprised of the chemotherapeutic camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of tumor cells to CPT while minimizing side effects.

OBJECTIVES:

• Determine the safety, toxicity, and the maximum tolerated dose (MTD) of CRLX101 when administered intravenously to subjects with advanced solid tumors.


Eligibility criteria: Inclusion Criteria:

* Male and female subjects \>18 years of age with advanced, histologically-confirmed solid tumors refractory to standard therapy or for which no standard therapy exists and who have evidence of disease progression documented since their prior therapy.
* Subjects must have measurable or evaluable disease.
* Subjects must not have received prior chemotherapy or radiation for \>/= 4 weeks prior to first dose of study drug.
* Subjects may be entered if they have received prior radiation therapy involving \</= 30% of the bone marrow. Any prior radiation therapy must have been administered \>/= 4 weeks prior to first dose of study drug and the subject must be recovered from the acute toxic effects of the treatment prior to study entry.
* Subjects may be enrolled with a history of treated brain metastases that are clinically stable for \>/= 4 weeks prior to first dose of study drug. Subjects may not be currently receiving dexamethasone.
* ECOG performance status of \< 2.
* Life expectancy of greater than 12 weeks.
* Subjects must have acceptable organ and marrow function at screening and pre-dose visits.
* Electrocardiogram without evidence of clinically significant conduction abnormalities or active ischemia as determined by the investigator and an acceptable QTc interval.
* The effects of CRLX101 on the developing human fetus are unknown, therefore, women of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation.
* Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

* Female subjects who are pregnant or nursing.
* Subjects who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to first dose of study drug or those who have not had adverse events return to baseline severity level or a severity level Grade 1 due to agents administered more than 4 weeks prior to first dose of study drug.
* Subjects with a history of congestive heart failure (CHF) requiring medical therapy.
* Subjects with serum amylase or lipase \> 1.5X upper limit of normal (ULN).
* Subjects with previous high dose chemotherapy with autologous stem cell rescue bone marrow transplantation.
* Use of any investigational agent or drug within 4 weeks prior to first dose of study drug.
* Metastatic disease to the CNS requiring treatment or radiation therapy.
* Subjects with known untreated brain metastases or treated brain metastases that have not been stable \>/= 4 weeks prior to first dose of study drug.
* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, hypertension, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements, as determined by the investigator.
* The presence of active coagulation disorder.
* Subjects with marked baseline prolongation of QT/QTc interval (QTc interval \>/= 470 msec for females and QTc interval \>/= 450 msec for males).
* Any prior treatment with a topoisomerase I inhibitor.
* Any major surgery \</= 4 weeks prior to first dose of study drug.
* Concurrent use of G-CSF or growth factors at the time of initiation of study drug.

Primary outcomes:
measure: To determine the safety, toxicity and maximum tolerated dose of CRLX101 when administered intravenously to subjects with advanced solid tumors.
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Virginia G. Piper Cancer Center
state: Arizona
city: Duarte
country: United States
facility: City of Hope National Medical Center
state: California
city: Farmington
country: United States
facility: San Juan Oncology Associates
state: New Mexico
Study officials:
affiliation: City of Hope National Medical Center
name: Yun Yen, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: Virginia G. Piper Cancer Center
name: Glenn Weiss, M.D.
role: PRINCIPAL_INVESTIGATOR
affiliation: San Juan Oncology Associates
name: Jeffrey D. Neidhart, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin Cancer Res. 2006 Mar 1;12(5):1606-14. doi: 10.1158/1078-0432.CCR-05-1566.
citation: Schluep T, Cheng J, Khin KT, Davis ME. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. Cancer Chemother Pharmacol. 2006 May;57(5):654-62. doi: 10.1007/s00280-005-0091-7. Epub 2005 Aug 26.
citation: Cheng J, Khin KT, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol Pharm. 2004 May-Jun;1(3):183-93. doi: 10.1021/mp049966y.